The middle of the week came with news from one of the most popular pharma companies right now due to its COVID-19 vaccine – Pfizer
Pfizer, the company that developed the first authorized COVID- 19 vaccine in the US, announced that it began in March an early-stage clinical trial of a new medicine for the disease. The new drug is a protease inhibitor and works by inhibiting an enzyme that the virus needs to replicate in human cells. These types of inhibitors are already being used in treating HIV and hepatitis C.
According to Pfizer CEO Albert Bourla, if everything goes smoothly and the FDA approves the drug, it will hit the shelves by the end of the year.
From the health experts’ perspective, the ingestible drug could be a game-changer because infected people could use it outside hospitals.
Besides the news drug, Pfizer is testing its vaccine in 6-months to 11-year-old children, after the company received from the FDA the authorization to expand its vaccine usage to adolescents aged between 12 – 15.
The market seemed to react positively to the news. At the moment of writing, Pfizer stock price is trading 0.57% higher.
Sources: cnbc.com, finance.yahoo.com
Los usuarios / lectores no deben confiar únicamente en la información presentada aquí y deben hacer su propia investigación / análisis leyendo también la investigación subyacente real. El contenido adjunto es genérico y no tiene en cuenta las circunstancias personales, la experiencia de inversión o la situación financiera actual.
Por lo tanto, Key Way Investments Ltd no aceptará ninguna responsabilidad por las pérdidas de los comerciantes debido al uso y el contenido de la información presentada en este documento. Rentabilidades y predicciones pasadas no garantizan resultados futuros.
